Clinical trials: Percutaneous Coronary Intervention Patients
Heart Injuries
Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention
Coronary heart disease has a high incidence and high death rate. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD).
- Trial name
- EODOPWCHD (NCT03095469)
- Testing
- Dexmedetomidine, 0.9%NaCl solution
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Total Occlusion (CTO)
FAPI Imaging Assessment of Chronic Total Occlusion
This registry will include consecutive patients presenting with at least one chronic total coronary occlusion (CTO) identified via coronary angiography or cardiac computed tomography angiography (CCTA) at our center.
- Trial name
- FACT (NCT06655922)
- Testing
- FAPI Imaging
- Where
- 2 sites in China
- Volunteers
- 167 people
- Sponsor
- Lin Zhao
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Coronary Artery Disease, Drug-eluting Stents
Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database
Current Status and Prognosis of Coronary artery disease patients treated with coronary intervention - Analysis of the Korean Nationwide Health Insurance Database
- Conditions
- Coronary Artery Disease, Drug-eluting Stents, Drug-coated Balloon
- Trial name
- NCT04778969
- Testing
- drug-eluting stent, drug-coated balloon
- Volunteers
- 200,000 people
- Sponsor
- Seoul National University Hospital
Acute Myocardial Infarction
Ischemic Time and Extent of Myocardial Infarction (MI) With Cardiac Magnetic Resonance Imaging (CMRI) in Patients With ST Elevation Myocardial Infarction (STEMI) and Primary Percutaneous Coronary Intervention (PCI) Study
This study will assess relationship between ischemic time and the extent of myocardial infarction with cardiac magnetic resonance image in patients with STEMI (ST elevation myocardial infarction) and primary percutaneous coronary…
- Trial name
- ITEMMRI (NCT01401881)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Medstar Health Research Institute
Myocardial Infarction, Percutaneous Coronary Intervention
Adjunctive, Low-dose tPA in Primary PCI for STEMI
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the…
- Trial name
- STRIVE (NCT03335839)
- Testing
- tissue plasminogen activator, Saline
- Where
- 3 sites in Canada
- Volunteers
- 210 people
- Sponsor
- Population Health Research Institute
Percutaneous Coronary Intervention
Exploring the Volume-Outcome Relationship for PCI Procedures Undertaken in a UK Context: A NICOR Study
The relationship between annual procedural volume and patient outcome remains a debated issue in the field of interventional medicine.
- Trial name
- NCT02184949
- Testing
- Percutaneous Coronary Intervention, Primary Percutaneous Coronary Intervention
- Where
- United Kingdom
- Volunteers
- 427,467 people
- Sponsor
- University College, London
Chronic Total Occlusion
CABG Versus PCI in Patients With Isolated LAD Chronic Total Occlusion
The aim of this study is to compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in the treatment of isolated chronic total occlusion (CTO) of the left anterior descending (LAD) artery in…
- Trial name
- RITUAL (NCT07373678)
- Testing
- Coronary Artery Bypass Grafting, Percutaneous Coronary Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 302 people
- Sponsor
- Mersin Medicalpark Hastanesi
Coronary Artery Disease, Myocardial Infarction
Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy
Clopidogrel is crucial as antiplatelet treatment in patients undergoing percutaneous coronary intervention (PCI) with stent implantation and during one year after PCI, to prevent atherothrombotic complications.
- Conditions
- Coronary Artery Disease, Myocardial Infarction, Heart Disease, Vascular Disease
- Trial name
- NCT01823185
- Testing
- clopidogrel, Ticagrelor or prasugrel
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 1,500 people
- Sponsor
- Imam Abdulrahman Bin Faisal University
Coronary Artery Disease, Angina Pectoris
SORT-OUT VI - Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®
To perform a randomized comparison between the BioMatrix Flex™ and the Resolute Integrity® stents in the treatment of unselected patients with ischemic heart disease.
- Trial name
- SO VI (NCT01956448)
- Testing
- Drug eluting stent
- Where
- 3 sites in Denmark
- Volunteers
- 2,800 people
- Sponsor
- Aarhus University Hospital Skejby
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Stable Angina
Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina
In this study the investigators will use careful scientific blinding of patient and their subsequent healthcare staff so that the investigators can determine exactly how much difference coronary angioplasty makes to symptoms and…
- Trial name
- ORBITA (NCT02062593)
- Testing
- Coronary angioplasty
- Where
- 5 sites in United Kingdom
- Volunteers
- 230 people
- Sponsor
- Imperial College London
Coronary Artery Disease
A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
This study is designed to determine the efficacy of REG1 compared to bivalirudin in preventing periprocedural ischemic complications and major bleeding in patients undergoing PCI as a treatment for CAD.
- Trial name
- Regulate (NCT01848106)
- Testing
- pegnivacogin/anivamersen, Bivalirudin
- Where
- United States
- Volunteers
- 3,232 people
- Sponsor
- Regado Biosciences, Inc.
Conservative Pharmacotherapy, Staged Percutaneous Coronary Intervention
Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction
To compare the different effect of conservative pharmacotherapy and Staged Percutaneous Coronary Intervention (SPCI) on significant non-culprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) at…
- Conditions
- Conservative Pharmacotherapy, Staged Percutaneous Coronary Intervention, Non-culprit Vessels, ST-Segment Elevation Myocardial Infarction
- Trial name
- CPVsSPCI (NCT02154919)
- Testing
- Percutaneous coronary intervention
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Beijing Shijitan Hospital, Capital Medical University
Coronary Microvascular Disease
Personalized Medicine Using Coronary Microvascular Function Measured in Patient With Percutaneous Coronary Intervention in Angina
The evidence demonstrating the importance of coronary microcirculation in the management of patients with coronary artery disease is growing.
- Trial name
- DECISIONING (NCT05178914)
- Testing
- Treatment adaptation
- Where
- France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Grenoble
Myocardial Infarction, Left Ventricular Remodeling
Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling
Purpose: The purpose of this study is to evaluate the impact of circulating miR-126 on left ventricular remodeling and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-segment elevation…
- Conditions
- Myocardial Infarction, Left Ventricular Remodeling, miR-126
- Trial name
- PMIR-miR-126 (NCT01875484)
- Where
- 17 sites in China
- Volunteers
- 1,200 people
- Sponsor
- Qilu Hospital of Shandong University
Focus of Study is STEMI
Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction
This study explores the potential cardioprotective properties of danegaptide when administered to patients with ST-Segment elevation myocardial infarction.
- Trial name
- NCT01977755
- Testing
- danegaptide
- Where
- Denmark
- Volunteers
- 591 people
- Sponsor
- Zealand Pharma
Coronary Artery Disease
Comparison of 1 Month vs. 12 Months DAPT in Patients Undergoing PCI With Genoss® DES
This study is a prospective, open-label, multicenter, randomized clinical trial to evaluate the efficacy of 1 month dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel followed by clopidogrel monotherapy, compared with…
- Trial name
- GENOSS-DAPT (NCT05770674)
- Testing
- 1 Month vs. 12 Months DAPT
- Where
- South Korea
- Volunteers
- 2,186 people
- Sponsor
- Kiyuk Chang
Coronary Artery Disease
CompArison of PCI in NaTive Arteries Versus ByPAss Grafts In PatieNts With Prior CABG (CAPTAIN)
Coronary atherosclerotic heart disease (CAD) has been considered the leading cause of death in both developed and developing countries.
- Trial name
- NCT05368597
- Testing
- PCI in native vessel or in bypass graft
- Where
- China
- Volunteers
- 1,491 people
- Sponsor
- Beijing Anzhen Hospital